China Medtech: China IVD expert call: Test/reagent pricing risks likely shift to 2027

Research evidence excerpt

China Medtech: China IVD expert call: Test/reagent pricing risks likely shift to 2027

Global Research

10 July 2026ab

China Medtech Equities

ChinaChina IVD expert call: Test/reagent pricing risks

likely shift to 2027 Healthcare

Jun Deng

Analyst

jun.deng@ubs.com

China IVD market update for Q226 +852-3712 2103

We hosted an expert call with Mr. Fang, an in-vitro diagnostics (IVD) distributor with over Emma Ma, CFA

15 years of industry experience. Key topics included: 1) market growth, channel Associate

inventory and the competitive landscape in Q226; 2) the potential impact of the S1460124070003

Diagnostics Services Price Items Guideline and implementation timeline; 3) the expert's emma-mc.ma@ubs.com

market growth estimates and views on potential competitive landscape in 2026-27. +86-21-3866 8981

Chen Chen, PhD

Q226: Overall sequential improvement but YoY declines for some categories Analyst

Per the expert, market performance by test category in Q226 was as follows: 1) S1460520100001

Chemiluminescent immunoassay (CLIA): +2%/-2% YoY in test volume/revenue, mainly chen-zb.chen@ubs.com

+86-10-5832 8201due to the price erosion from thyroid function volume-based procurement (VBP). 2)

Clinical chemistry: -2% YoY in volume and revenue mainly due to test unbundling which Tomoko Yoshihara

kicked in during H225. 3) Haematology: organic growth of 4% YoY in volume and Analyst

revenue with relatively low influenza incidence after March. 4) Haemostasis: 3% YoY tomoko.yoshihara@ubs.com

+81-3-5208 6212growth in volume and revenue, with growth constrained by test unbundling policies. 5)

Molecular testing: -6%/-8% YoY in volume/revenue due to lower respiratory disease Graham Doyle

testing demand and intensified competition. 6) Microbiological testing: 3% YoY growth Analyst